People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) — either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.
Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have showed. People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) — either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.
The results from the clinical trial called “select-d” suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with cancer. “Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot,” said lead author Annie Young, Professor at University of Warwick in the Britain.
Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, pancreatic and gastric tumours as well as chemotherapy, the researcher said.
For the “select-d” trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE. Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11% in those receiving dalteparin. The results for secondary outcomes were mixed, the researcher said.
In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6%) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13%) with rivaroxaban compared to those having low molecular weight heparin (4%).
The reason for increased bleeding is not known. It may be because rivaroxaban is more ‘potent’, the paper published in the Journal of Clinical Oncology said.
[“source=hindustantimes”]
